Incyte Tax Provision vs Extraordinary Items Analysis
INCY Stock | USD 57.19 0.09 0.16% |
Incyte financial indicator trend analysis is infinitely more than just investigating Incyte recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Incyte is a good investment. Please check the relationship between Incyte Tax Provision and its Extraordinary Items accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Incyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.
Tax Provision vs Extraordinary Items
Tax Provision vs Extraordinary Items Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Incyte Tax Provision account and Extraordinary Items. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Incyte's Tax Provision and Extraordinary Items is 0.11. Overlapping area represents the amount of variation of Tax Provision that can explain the historical movement of Extraordinary Items in the same time period over historical financial statements of Incyte, assuming nothing else is changed. The correlation between historical values of Incyte's Tax Provision and Extraordinary Items is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Tax Provision of Incyte are associated (or correlated) with its Extraordinary Items. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Extraordinary Items has no effect on the direction of Tax Provision i.e., Incyte's Tax Provision and Extraordinary Items go up and down completely randomly.
Correlation Coefficient | 0.11 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Extraordinary Items
Most indicators from Incyte's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Incyte current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Incyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.At this time, Incyte's Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 229.8 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.30 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 2.2B | 2.6B | 2.8B | 2.9B | Cost Of Revenue | 151.0M | 207.0M | 255M | 267.8M |
Incyte fundamental ratios Correlations
Click cells to compare fundamentals
Incyte Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Incyte fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 3.4B | 3.6B | 4.9B | 5.8B | 6.8B | 7.1B | |
Short Long Term Debt Total | 50.9M | 34.9M | 34.3M | 44.6M | 38.3M | 36.4M | |
Other Current Liab | 76.1M | 86.2M | 82.8M | 469.7M | 111.7M | 70.6M | |
Total Current Liabilities | 500.5M | 648.8M | 885.1M | 1.2B | 1.2B | 1.3B | |
Total Stockholder Equity | 2.6B | 2.6B | 3.8B | 4.4B | 5.2B | 5.4B | |
Property Plant And Equipment Net | 406.6M | 588.1M | 751.5M | 765.6M | 777.0M | 815.9M | |
Net Debt | (1.8B) | (1.5B) | (2.0B) | (2.9B) | (3.2B) | (3.0B) | |
Retained Earnings | (1.4B) | (1.7B) | (777.9M) | (437.2M) | 160.4M | 168.4M | |
Accounts Payable | 83.6M | 98.8M | 172.1M | 277.5M | 109.6M | 115.1M | |
Cash | 1.8B | 1.5B | 2.1B | 3.0B | 3.2B | 3.4B | |
Non Current Assets Total | 889.7M | 1.1B | 1.7B | 1.6B | 2.1B | 2.2B | |
Cash And Short Term Investments | 2.1B | 1.8B | 2.3B | 3.2B | 3.7B | 3.8B | |
Common Stock Shares Outstanding | 217.7M | 218.1M | 222.1M | 224.0M | 225.9M | 130.7M | |
Liabilities And Stockholders Equity | 3.4B | 3.6B | 4.9B | 5.8B | 6.8B | 7.1B | |
Non Current Liabilities Total | 327.9M | 300.9M | 278.3M | 254.3M | 351.9M | 340.4M | |
Other Current Assets | 94.2M | 103.3M | 165.3M | 167.0M | 182.8M | 192.0M | |
Other Stockholder Equity | 4.0B | 4.4B | 4.6B | 4.8B | 5.0B | 5.3B | |
Total Liab | 828.3M | 949.7M | 1.2B | 1.5B | 1.6B | 1.7B | |
Total Current Assets | 2.5B | 2.4B | 3.2B | 4.2B | 4.6B | 4.9B | |
Short Term Debt | 28.3M | 15.0M | 13.2M | 11.4M | 9.1M | 8.7M | |
Non Currrent Assets Other | 55.6M | 62.8M | 68.1M | 106.1M | 260.9M | 274.0M | |
Net Receivables | 308.8M | 482.0M | 616.3M | 644.9M | 743.6M | 780.7M | |
Property Plant And Equipment Gross | 406.6M | 559.6M | 751.5M | 765.6M | 1.0B | 1.1B | |
Accumulated Other Comprehensive Income | (15.5M) | (15.4M) | (19.5M) | 15.1M | 13.1M | 13.8M | |
Intangible Assets | 193.8M | 172.3M | 150.8M | 129.2M | 123.5M | 74.2M | |
Short Term Investments | 284.9M | 288.4M | 290.8M | 287.5M | 442.7M | 464.8M | |
Other Assets | 55.6M | 25.1M | 467.5M | 564.0M | 648.6M | 681.1M | |
Common Stock Total Equity | 216K | 219K | 221K | 223K | 256.5K | 154K | |
Common Stock | 216K | 219K | 221K | 223K | 224K | 157.9K | |
Property Plant Equipment | 377.6M | 559.6M | 723.9M | 739.3M | 850.2M | 892.7M | |
Current Deferred Revenue | 312.4M | 448.9M | 617.0M | 457.9M | 1.0B | 1.1B | |
Other Liab | 271.2M | 266M | 244M | 269.6M | 310.0M | 156.9M | |
Inventory | 16.5M | 36.0M | 56.9M | 121.0M | 63.0M | 66.1M | |
Net Tangible Assets | 2.2B | 2.3B | 3.5B | 4.1B | 4.7B | 4.9B | |
Retained Earnings Total Equity | (1.4B) | (1.7B) | (777.9M) | (437.2M) | (502.8M) | (527.9M) | |
Capital Surpluse | 4.0B | 4.4B | 4.6B | 4.8B | 5.5B | 3.4B | |
Non Current Liabilities Other | 315.0M | 318.5M | 309.0M | 313.8M | 322.7M | 278.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Incyte offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Incyte's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Incyte Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Incyte Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Incyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.Note that the Incyte information on this page should be used as a complementary analysis to other Incyte's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Incyte Stock analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Incyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Incyte. If investors know Incyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Incyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.705 | Earnings Share 3.3 | Revenue Per Share 16.82 | Quarterly Revenue Growth 0.089 | Return On Assets 0.0689 |
The market value of Incyte is measured differently than its book value, which is the value of Incyte that is recorded on the company's balance sheet. Investors also form their own opinion of Incyte's value that differs from its market value or its book value, called intrinsic value, which is Incyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Incyte's market value can be influenced by many factors that don't directly affect Incyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Incyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Incyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Incyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.